Apoptosis as a practical target for identifying anticancer agents of marine origin

Osamu Ohno, Toshiaki Teruya, Kiyotake Suenaga, Daisuke Uemura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Natural products and their synthetic analogs are widely used as anticancer drugs. Many anticancer drugs originated from cytotoxic compounds, and most have been shown to induce apoptosis in cancer cells. Based on the variety of their modes of action, the identification of new cytotoxic compounds may lead to the discovery of new types of drugs. Recently, much attention has been given to the metabolites of marine organisms due to their strong cytotoxicity. For example, eribulin mesylate, a synthetic analog of halichondrin B isolated from H. okadai Kadota, has been developed as an anticancer drug. Novel cytotoxic substances, such as halichonines, bisebromoamides, and biselyngbyasides, have been isolated from marine organisms as apoptosis-inducing agents. All of these compounds may possess therapeutic potential, and thus, efforts to identify new apoptosis-inducing agents of marine origin may contribute to the discovery of new pharmaceuticals.

Original languageEnglish
Pages (from-to)33-41
Number of pages9
JournalForum on Immunopathological Diseases and Therapeutics
Volume4
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Antineoplastic Agents
Apoptosis
Aquatic Organisms
eribulin
Pharmaceutical Preparations
Lead compounds
Drug Discovery
Biological Products
Cytotoxicity
Metabolites
Cells
Neoplasms
Therapeutics

Keywords

  • Anticancer drug
  • Apoptosis
  • Bisebromoamide
  • Biselyngbyaside
  • Marine organism

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Biochemistry
  • Biotechnology

Cite this

Apoptosis as a practical target for identifying anticancer agents of marine origin. / Ohno, Osamu; Teruya, Toshiaki; Suenaga, Kiyotake; Uemura, Daisuke.

In: Forum on Immunopathological Diseases and Therapeutics, Vol. 4, No. 1, 2013, p. 33-41.

Research output: Contribution to journalArticle

@article{4dc069fb3a7646ceb0570e807ed07a48,
title = "Apoptosis as a practical target for identifying anticancer agents of marine origin",
abstract = "Natural products and their synthetic analogs are widely used as anticancer drugs. Many anticancer drugs originated from cytotoxic compounds, and most have been shown to induce apoptosis in cancer cells. Based on the variety of their modes of action, the identification of new cytotoxic compounds may lead to the discovery of new types of drugs. Recently, much attention has been given to the metabolites of marine organisms due to their strong cytotoxicity. For example, eribulin mesylate, a synthetic analog of halichondrin B isolated from H. okadai Kadota, has been developed as an anticancer drug. Novel cytotoxic substances, such as halichonines, bisebromoamides, and biselyngbyasides, have been isolated from marine organisms as apoptosis-inducing agents. All of these compounds may possess therapeutic potential, and thus, efforts to identify new apoptosis-inducing agents of marine origin may contribute to the discovery of new pharmaceuticals.",
keywords = "Anticancer drug, Apoptosis, Bisebromoamide, Biselyngbyaside, Marine organism",
author = "Osamu Ohno and Toshiaki Teruya and Kiyotake Suenaga and Daisuke Uemura",
year = "2013",
doi = "10.1615/ForumImmunDisTher.2013008307",
language = "English",
volume = "4",
pages = "33--41",
journal = "Forum on Immunopathological Diseases and Therapeutics",
issn = "2151-8017",
publisher = "Begell House Inc.",
number = "1",

}

TY - JOUR

T1 - Apoptosis as a practical target for identifying anticancer agents of marine origin

AU - Ohno, Osamu

AU - Teruya, Toshiaki

AU - Suenaga, Kiyotake

AU - Uemura, Daisuke

PY - 2013

Y1 - 2013

N2 - Natural products and their synthetic analogs are widely used as anticancer drugs. Many anticancer drugs originated from cytotoxic compounds, and most have been shown to induce apoptosis in cancer cells. Based on the variety of their modes of action, the identification of new cytotoxic compounds may lead to the discovery of new types of drugs. Recently, much attention has been given to the metabolites of marine organisms due to their strong cytotoxicity. For example, eribulin mesylate, a synthetic analog of halichondrin B isolated from H. okadai Kadota, has been developed as an anticancer drug. Novel cytotoxic substances, such as halichonines, bisebromoamides, and biselyngbyasides, have been isolated from marine organisms as apoptosis-inducing agents. All of these compounds may possess therapeutic potential, and thus, efforts to identify new apoptosis-inducing agents of marine origin may contribute to the discovery of new pharmaceuticals.

AB - Natural products and their synthetic analogs are widely used as anticancer drugs. Many anticancer drugs originated from cytotoxic compounds, and most have been shown to induce apoptosis in cancer cells. Based on the variety of their modes of action, the identification of new cytotoxic compounds may lead to the discovery of new types of drugs. Recently, much attention has been given to the metabolites of marine organisms due to their strong cytotoxicity. For example, eribulin mesylate, a synthetic analog of halichondrin B isolated from H. okadai Kadota, has been developed as an anticancer drug. Novel cytotoxic substances, such as halichonines, bisebromoamides, and biselyngbyasides, have been isolated from marine organisms as apoptosis-inducing agents. All of these compounds may possess therapeutic potential, and thus, efforts to identify new apoptosis-inducing agents of marine origin may contribute to the discovery of new pharmaceuticals.

KW - Anticancer drug

KW - Apoptosis

KW - Bisebromoamide

KW - Biselyngbyaside

KW - Marine organism

UR - http://www.scopus.com/inward/record.url?scp=84884995642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884995642&partnerID=8YFLogxK

U2 - 10.1615/ForumImmunDisTher.2013008307

DO - 10.1615/ForumImmunDisTher.2013008307

M3 - Article

AN - SCOPUS:84884995642

VL - 4

SP - 33

EP - 41

JO - Forum on Immunopathological Diseases and Therapeutics

JF - Forum on Immunopathological Diseases and Therapeutics

SN - 2151-8017

IS - 1

ER -